Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, et al. - Researchers distinguished patients with well-differentiated (Ki67% ≤ 20%), metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with first-line somatostatin analogue (SSA) monotherapy from the Spanish R-GETNE registry in order to match survival-based outcomes from real-world clinical practice vs randomized clinical trials (RCTs). A Bayesian Cox model was applied to assess the therapeutic effect. The study included a total of 535 patients with a median age of 62 years (range: 26-89). This research assessed the external validity of RCTs examining SSAs in the real world, as well as the main effect-modifying factors (progression status, symptoms, tumor site, specific metastases, and analytical data). Half of the patients received octreotide LAR (n=266) and half, lanreotide autogel (n=269). The median PFS was 28.0 months for octreotide vs 30.1 months for lanreotide. The outcomes revealed that both octreotide LAR and lanreotide autogel had a similar effect on PFS. As per the findings, both represent valid alternatives in patients with well-differentiated, metastatic GEP-NENs.